Table IV.
Estimation of blood management cost savings (€+) or incremental costs (€−) per patient undergoing surgery for total hip or knee arthroplasty, managed with four different intravenous iron formulations (n=100), compared to those from the control group (n=100), at different allogeneic transfusion rates.
| Control | IS | LMWID | FCM | MNF |
|---|---|---|---|---|
|
| ||||
| 10% ALO-1 | 10% ALO-1 | 10% ALO-1 | 10% ALO-1 | |
|
|
||||
| 35% ALO-1 | € +28.9 | € +21.9 | € −4.1 | € −4.1 |
| 30% ALO-1 | € +2.8 | € −4.2 | € −30.2 | € −30.2 |
| 25% ALO-1 | € −23.2 | € −30.2 | € −56.2* | € −56.2* |
| 20% ALO-1 | € −49.3* | € −56.3* | € −82.3* | € −82.3* |
| 15% ALO-1 | € −75.4* | € −82.4* | € −108.4* | € −108.4* |
|
|
||||
| 10% ALO-2 | 10% ALO-2 | 10% ALO-2 | 10% ALO-2 | |
|
|
||||
| 35% ALO-2 | € +108.9* | € +101.9* | € +75.9 | € +75.9 |
| 30% ALO-2 | € +66.8 | € +59.8 | € +33.8 | € +33.8 |
| 25% ALO-2 | € +24.8 | € +17.8 | € −8.2 | € −8.2 |
| 20% ALO-2 | € −17.3 | € −24.3 | € −50.3 | € −50.3 |
| 15% ALO-2 | € −59.4 | € −66.4 | € −92.4* | € −92.4* |
|
|
||||
| 10% ALO-3 | 10% ALO-3 | 10% ALO-3 | 10% ALO-3 | |
|
|
||||
| 35% ALO-3 | € +188.9* | € +181.9* | € +155.9* | € +155.9* |
| 30% ALO-3 | € +130.8* | € +123.8* | € +97.8 | € +97.8 |
| 25% ALO-3 | € +72.8 | € +65.8 | € +39.8 | € +39.8 |
| 20% ALO-3 | € +14.7 | € +7.7 | € −18.3 | € −18.3 |
| 15% ALO-3 | € −43.4 | € −50.4 | € −76.4 | € −76.4 |
Legend IS: iron sucrose; LMWID: low molecular weight iron dextran; FCM: ferric carboxymaltose; MNF: iron isomaltoside 1000.
Data calculations take into account the mean cost per patient for both intravenous iron and allogeneic blood management (cost scenario ALO-1) and a hospital stay prolonged by 1 day (cost scenario ALO-2) or 2 days (cost scenario ALO-3) in patients receiving allogeneic red cell transfusion (see Table III).
p<0.05; bold font for cost saving, shadowed cell for incremental cost.